Bristol Myers Squibb Company $BMY Shares Bought by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 7.1% in the third quarter, Holdings Channel.com reports. The institutional investor owned 748,983 shares of the biopharmaceutical company’s stock after purchasing an additional 49,845 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Bristol Myers Squibb were worth $33,779,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of BMY. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb in the 2nd quarter worth approximately $25,000. Harbor Capital Advisors Inc. grew its position in shares of Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 313 shares in the last quarter. Total Investment Management Inc. acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $38,000. Twin Peaks Wealth Advisors LLC purchased a new position in Bristol Myers Squibb during the second quarter worth approximately $40,000. Finally, Mark Sheptoff Financial Planning LLC lifted its position in Bristol Myers Squibb by 233.3% during the second quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 700 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Trading Down 1.6%

NYSE BMY opened at $59.91 on Thursday. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. The stock has a market capitalization of $121.96 billion, a P/E ratio of 17.37, a PEG ratio of 0.17 and a beta of 0.29. The firm’s 50-day moving average is $55.00 and its two-hundred day moving average is $49.28. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 70.30%. The company had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. During the same period last year, the firm posted $1.67 earnings per share. Bristol Myers Squibb’s revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were given a dividend of $0.63 per share. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BMY. Leerink Partners upped their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Truist Financial set a $65.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, December 3rd. Scotiabank restated a “sector perform” rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Guggenheim reaffirmed a “buy” rating and set a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, HSBC reissued a “hold” rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Eight analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $59.20.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.